Sustained-release Ofev Shows Better Absorption Over Soft Capsules, Study Suggests

Cancer Therapy Panobinostat Shows Anti-fibrotic Effects in IPF Fibroblasts, Preclinical Study Reports

Panobinostat, an approved treatment for multiple myeloma, exerts anti-fibrotic activity, inducing cell death and reducing the proliferation of lab-grown fibroblasts from idiopathic pulmonary fibrosis (IPF) patients, a preclinical study reports. The data also suggest that, despite an ability to inhibit cellular pathways involved in fibrosis, approved IPF…

Grieving the Workplace Skills I’ve Lost Due to IPF

Most of society thinks of grief in the context of a loved one’s death. However, people with chronic illness grieve other things as well, such as personal losses inflicted by disease. Since my 2016 idiopathic pulmonary fibrosis (IPF) diagnosis, I have become increasingly aware of the things I’ve…

Esbriet Extends IPF Patient Survival, Real-world Study Reports

Esbriet (pirfenidone) can improve survival rates of idiopathic pulmonary fibrosis (IPF) patients by 30 percent, a real-world retrospective analysis shows. The study, “Pirfenidone improves survival in IPF: results from a real-life study,” was published in the journal BMC Pulmonary Medicine. Genentech’s Esbriet is an approved…